Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Histopathologic Characterization of Mogamulizumab-associated Rash.

Tytuł :
Histopathologic Characterization of Mogamulizumab-associated Rash.
Autorzy :
Wang JY; Department of Dermatology, Stanford University School of Medicine, Redwood City.; Department of Pathology.
Hirotsu KE; Department of Dermatology, Stanford University School of Medicine, Redwood City.
Neal TM; Department of Dermatology, Stanford University School of Medicine, Redwood City.
Raghavan SS; Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA.
Kwong BY; Department of Dermatology, Stanford University School of Medicine, Redwood City.
Khodadoust MS; Department of Dermatology, Stanford University School of Medicine, Redwood City.; Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA.
Brown RA; Department of Dermatology, Stanford University School of Medicine, Redwood City.; Department of Pathology.
Novoa RA; Department of Dermatology, Stanford University School of Medicine, Redwood City.; Department of Pathology.
Kim YH; Department of Dermatology, Stanford University School of Medicine, Redwood City.; Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA.
Rieger KE; Department of Dermatology, Stanford University School of Medicine, Redwood City.; Department of Pathology.
Pokaż więcej
Źródło :
The American journal of surgical pathology [Am J Surg Pathol] 2020 Dec; Vol. 44 (12), pp. 1666-1676.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Publication: <2015- > : Philadelphia, PA : Wolters Kluwer Health, Inc.
Original Publication: New York, Masson.
MeSH Terms :
Antibodies, Monoclonal, Humanized/*adverse effects
Antineoplastic Agents/*adverse effects
Drug Eruptions/*etiology
Exanthema/*chemically induced
Skin/*drug effects
T-Lymphocytes/*drug effects
CD4-CD8 Ratio ; Drug Eruptions/genetics ; Drug Eruptions/immunology ; Drug Eruptions/pathology ; Exanthema/genetics ; Exanthema/immunology ; Exanthema/pathology ; Female ; Genes, T-Cell Receptor ; High-Throughput Nucleotide Sequencing ; Humans ; Male ; Skin/immunology ; Skin/pathology ; T-Lymphocytes/immunology
References :
Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16:1520–1531.
Ferenczi K, Fuhlbrigge RC, Pinkus J, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119:1405–1410.
Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–842.
Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157–1163.
Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1192–1204.
Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–3115.
Kasamon YL, Chen H, de Claro RA, et al. FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and sezary syndrome. Clin Cancer Res. 2019;25:7275–7280.
Ishitsuka K, Yurimoto S, Kawamura K, et al. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance. Int J Hematol. 2017;106:522–532.
Tokunaga M, Yonekura K, Nakamura D, et al. Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma. Br J Haematol. 2018;181:539–542.
Yonekura K, Kanzaki T, Gunshin K, et al. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis. J Dermatol. 2014;41:239–244.
Chen L, Carson KR, Staser KW, et al. Mogamulizumab-associated cutaneous granulomatous drug eruption mimicking mycosis fungoides but possibly indicating durable clinical response. JAMA Dermatol. 2019;29:968–971.
Ito A, Sugita K, Adachi K, et al. CD8+ T-cell-mediated interface dermatitis after CCR4+ T-cell depletion by mogamulizumab treatment of adult T-cell leukaemia/lymphoma. Acta Derm Venereol. 2017;97:377–378.
Tani N, Sugita K, Ito A, et al. CD8+ T cell-mediated interface dermatitis during combination chemotherapy with mogamulizumab in a patient with adult T-cell leukaemia/lymphoma. Clin Exp Dermatol. 2018;43:736–737.
Yonekura K, Tokunaga M, Kawakami N, et al. Cutaneous adverse reaction to mogamulizumab may indicate favourable prognosis in adult T-cell leukaemia-lymphoma. Acta Derm Venereol. 2016;96:1000–1002.
Kanno K, Honma M, Ishida-Yamamoto A. Cutaneous adverse reaction of mogamulizumab, an anti-CC chemokine receptor 4 monoclonal antibody: Shared histopathological features with thymoma-associated multi-organ autoimmunity. J Dermatol. 2017;44:e117–e118.
Suzuki Y, Saito M, Ishii T, et al. Mogamulizumab treatment elicits autoantibodies attacking the skin in patients with adult T-cell leukemia-lymphoma. Clin Cancer Res. 2019;25:4388–4399.
Masuda Y, Tatsuno K, Kitano S, et al. Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms. J Eur Acad Dermatol Venereol. 2018;32:1456–1460.
Tatsuno K, Sano T, Fukuchi K, et al. Emergence of photosensitivity with decreased Treg cells in a patient with mycosis fungoides treated with anti-CC chemokine receptor 4 antibody mogamulizumab. Acta Derm Venereol. 2016;96:420–421.
Honda T, Hishizawa M, Kataoka TR, et al. Stevens-Johnson syndrome associated with mogamulizumab-induced deficiency of regulatory T cells in an adult T-cell leukaemia patient. Acta Derm Venereol. 2015;95:606–607.
Amakata M, Teraki Y. Depletion of regulatory FoxP3. Int J Dermatol. 2019;58:e247–e249.
Ni X, Jorgensen JL, Goswami M, et al. Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome. Clin Cancer Res. 2015;21:274–285.
Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 2013;110:17945–17950.
Kurose K, Ohue Y, Wada H, et al. Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin Cancer Res. 2015;21:4327–4336.
Zhang B, Beck AH, Taube JM, et al. Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses. J Mol Diagn. 2010;12:320–327.
Weng WK, Armstrong R, Arai S, et al. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Sci Transl Med. 2013;5:214ra171.
Kirsch IR, Watanabe R, O’Malley JT, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7:308ra158.
Adaptive Biotechnologies. clonoSEQ® Assay Technical Information; 2018. Available at: https://clonoSEQ.com/technical-summary. Accessed February 2, 2020.
Wick MR. Psoriasiform dermatitides: A brief review. Semin Diagn Pathol. 2017;34:220–225.
Deschaine MA, Lehman JS. The interface reaction pattern in the skin: an integrated review of clinical and pathological features. Hum Pathol. 2019;91:86–113.
Justiniano H, Berlingeri-Ramos AC, Sánchez JL. Pattern analysis of drug-induced skin diseases. Am J Dermatopathol. 2008;30:352–369.
Naim M, Weyers W, Metze D. Histopathologic features of exanthematous drug eruptions of the macular and papular type. Am J Dermatopathol. 2011;33:695–704.
Shapiro PE, Pinto FJ. The histologic spectrum of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma). A review of 222 biopsies, including newly described patterns and the earliest pathologic changes. Am J Surg Pathol. 1994;18:645–667.
Nickoloff BJ. Light-microscopic assessment of 100 patients with patch/plaque-stage mycosis fungoides. Am J Dermatopathol. 1988;10:469–477.
Yeh YA, Hudson AR, Prieto VG, et al. Reassessment of lymphocytic atypia in the diagnosis of mycosis fungoides. Mod Pathol. 2001;14:285–288.
Guitart J, Kennedy J, Ronan S, et al. Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting. J Cutan Pathol. 2001;28:174–183.
Ansell SM. Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture? Leuk Lymphoma. 2019;60:1114–1115.
Husnain M, Mackrides N, Vega F, et al. CD4+/CD8+ immunophenotype switching as a marker for intraocular and CNS involvement in mycosis fungoides. Leuk Lymphoma. 2019;60:1308–1311.
Braue JA, Daniels AB, Zwerner JP, et al. Intraocular involvement of mycosis fungoides associated with immunophenotypic switch from CD4(+) to CD8(+). Blood. 2018;131:932–935.
Endo C, Naka Y, Miyagaki T, et al. Immunophenotypic shift from CD4(+) to CD8(+) in mycosis fungoides. Br J Dermatol. 2016;175:830–833.
Okada S, Nannya Y, Ota S, et al. Cutaneous T-cell lymphoma (mycosis fungoides) relapsed with different immunological phenotype after bone marrow transplant. Br J Dermatol. 2010;162:229–230.
Aung PP, Climent F, Muzzafar T, et al. Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases. J Cutan Pathol. 2014;41:51–57.
Sufficool KE, Lockwood CM, Abel HJ, et al. T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides. J Am Acad Dermatol. 2015;73:228.e2–236.e2.
Tohyama M, Hashimoto K. Immunological mechanisms of epidermal damage in toxic epidermal necrolysis. Curr Opin Allergy Clin Immunol. 2012;12:376–382.
Mavin E, Ahmed SS, O’Boyle G, et al. Regulatory T cells inhibit CD8(+) T-cell tissue invasion in human skin graft-versus-host reactions. Transplantation. 2012;94:456–464.
Ujiie H. Regulatory T cells in autoimmune skin diseases. Exp Dermatol. 2019;28:642–646.
Dai J, Almazan TH, Hong EK, et al. Potential association of anti-CCR4 antibody mogamulizumab and graft-vs-host disease in patients with mycosis fungoides and Sézary syndrome. JAMA Dermatol. 2018;154:728–730.
Ishida T, Ito A, Sato F, et al. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci. 2013;104:647–650.
Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34:3426–3433.
Bonnet P, Battistella M, Roelens M, et al. Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab. Br J Dermatol. 2019;180:419–420.
Substance Nomenclature :
0 (Antibodies, Monoclonal, Humanized)
0 (Antineoplastic Agents)
YI437801BE (mogamulizumab)
Entry Date(s) :
Date Created: 20200925 Date Completed: 20210111 Latest Revision: 20210131
Update Code :
20210210
DOI :
10.1097/PAS.0000000000001587
PMID :
32976123
Czasopismo naukowe
Rash is one of the most common adverse events observed with mogamulizumab, an anti-C-C chemokine receptor 4 monoclonal antibody approved for previously treated mycosis fungoides (MF) and Sezary syndrome (SS). Given the nonspecific clinical presentations of this rash, histopathologic distinction from MF/SS is critical for informing clinical management. We performed a comprehensive characterization of the histopathologic findings in mogamulizumab-associated rash (MAR) with the integration of high-throughput sequencing of T-cell receptor (TCR) genes. Fifty-two biopsy specimens from 19 patients were evaluated retrospectively. Three major histologic reaction patterns were identified: spongiotic/psoriasiform dermatitis (33/52), interface dermatitis (11/52), and granulomatous dermatitis (8/52). Almost half of the specimens (21/52) showed at least 2 of these reaction patterns concurrently. Dermal eosinophils were not a consistent feature, being present in only half (27/52) of specimens and prominent in only 3. Features mimicking MF/SS, including lymphocyte exocytosis, lamellar fibroplasia, and adnexal involvement, were commonly seen but tended to be focal and mild. In 38/43 specimens with available immunohistochemistry, intraepidermal lymphocytes demonstrated a CD4:CD8 ratio ≤1 : 1. Low background levels of the patient's previously identified MF/SS-associated TCR sequence(s) were demonstrated in 20/46 specimens analyzed by high-throughput sequencing of TCR. We conclude that MAR may demonstrate diverse histologic features. Findings that may distinguish MAR from MF/SS include the inverted or normalized CD4:CD8 ratio within intraepidermal lymphocytes and demonstration of absent or nondominant levels of disease-associated TCR sequences. Correlation with the clinical findings and immunohistochemical and molecular characterization of the patient's MF/SS before mogamulizumab, when possible, may facilitate recognition of MAR.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies